Novo Nordisk A/S: Diabetes Mellitus, Type 2 trials

The registry lists 633 Diabetes Mellitus, Type 2 studies with Novo Nordisk A/S as lead sponsor. 22 are open to participants now and 175 have results posted.

Phase 1 122Phase 2 37Phase 3 184Phase 4 75No phase 215(a study in two phases counts in both)

Studies

Page 4 of 7. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and GlargineCompletedNCT03960814
• A Research Study of How Overdosing of a New Once Weekly Medicine NNC0148-0287 C (Insulin 287) Influences the Blood Sugar Level in People With Type 2 DiabetesCompletedNCT03945656Phase 1
• A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)CompletedNCT03929679
• A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical RoutineCompletedNCT03888157
• A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK)CompletedNCT03876015
• A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in AlgeriaWithdrawnNCT03862690
• A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab EmiratesCompletedNCT03823339
• A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 DiabetesActive, not recruitingNCT03811561Phase 3
• An International Survey of the Occurrence of Cardiovascular Disease Among Patients With Type 2 DiabetesCompletedNCT03811288
• A Study of People With Type 2 Diabetes Who Have Diseases That Affect the Heart and Blood Vessels. The Study Will Also Look at the Treatment of a Group of These People in Hospitals in PortugalCompletedNCT03797885
• A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or TogetherCompletedNCT03789578Phase 1
• An International Survey of the Occurrence of Diseases That Affects the Heart and Blood Vessels Among People With Type 2 DiabetesCompletedNCT03786406
• A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Saudi ArabiaCompletedNCT03785522
• RESILIENT: A Research Study, Looking at How Ryzodeg® Works in People With Type 2 Diabetes in Local Clinical Practice in JapanCompletedNCT03745157
• A Research Study of How a New Medicine NNC0148-0287 C (Insulin 287) Works in the Body of People With Kidney ProblemsCompletedNCT03723785Phase 1
• A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes MellitusCompletedNCT03674866
• A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)CompletedNCT03648281
• Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy MenCompletedNCT03638778Phase 1
• A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)CompletedNCT03631186
• First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.CompletedNCT03617081Phase 1
• A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)CompletedNCT03611322Phase 1
• A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection ToolsCompletedNCT03598621Phase 1
• A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy SubjectsCompletedNCT03466567Phase 1
• A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical PracticeCompletedNCT03457012
• First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.CompletedNCT03444467Phase 1
• A Regulatory Post Marketing Surveillance (rPMS) Study of Ryzodeg® FlexTouch® (Insulin Degludec /Insulin Aspart) to Evaluate Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice in KoreaCompletedNCT03416855
• A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM)CompletedNCT03374774
• A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese SubjectsCompletedNCT03292185Phase 1
• A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese SubjectsCompletedNCT03288740Phase 1
• Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male SubjectsCompletedNCT03144271Phase 1
• Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in IndiaWithdrawnNCT03070704
• A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 DiabetesCompletedNCT02964104Phase 1
• A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes MellitusCompletedNCT02933853Phase 1
• Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.CompletedNCT02877355Phase 1
• A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal FemalesCompletedNCT02845219Phase 1
• A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 DiabetesCompletedNCT02773381Phase 1
• A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes MellitusCompletedNCT02754817
• Investigating the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes MellitusCompletedNCT02662114
• A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen®CompletedNCT02627287Phase 1
• Development of Pre-pregnancy Intervention to Reduce the Risk of Diabetes and PrediabetesCompletedNCT02617693Phase 4
• Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial ParticipantsCompletedNCT02608853
• A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy SubjectsCompletedNCT02479022Phase 1
• Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic TherapyCompletedNCT02470039Phase 2
• Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes MellitusCompletedNCT02392117
• Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)CompletedNCT02321878
• A Survey on Low Blod Sugar Among Insulin-treated Patients With DiabetesCompletedNCT02306681
• Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily PracticeCompletedNCT02255266
• A Survey on Hypoglycaemia Among Insulin-treated Patients With DiabetesCompletedNCT02230631
• Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in IndiaCompletedNCT02230618
• A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 DiabetesCompletedNCT02212067Phase 1
• Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic FunctionCompletedNCT02210871Phase 1
• A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With MetforminCompletedNCT02205528Phase 2
• A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian SubjectsCompletedNCT02161588Phase 1
• A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 DiabetesCompletedNCT02148861Phase 1
• A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 DiabetesCompletedNCT02147431Phase 1
• A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian SubjectsCompletedNCT02146079Phase 1
• A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in IndiaCompletedNCT02117622
• A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in SwedenCompletedNCT02077946
• A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh, Indonesia, Malaysia, Philippines, Sri Lanka and VietnamCompletedNCT02066766
• Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy SubjectsCompletedNCT02022254Phase 1
• Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic ImpairmentCompletedNCT02016911Phase 1
• Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal FunctionCompletedNCT02014259Phase 1
• Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®CompletedNCT01984372
• A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Sri LankaWithdrawnNCT01957592
• GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes MellitusCompletedNCT01950650
• GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes MellitusCompletedNCT01950637
• A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in IndonesiaCompletedNCT01934686
• A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in MalaysiaCompletedNCT01934673
• A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy SubjectsCompletedNCT01916174Phase 1
• Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year PeriodCompletedNCT01900834
• An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy RegistryCompletedNCT01892319
• Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in EuropeCompletedNCT01890993
• A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in BangladeshCompletedNCT01877200
• Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male SubjectsCompletedNCT01866748Phase 1
• Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With DiabetesCompletedNCT01865305Phase 1
• Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 DiabetesCompletedNCT01865292Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Explorative Formulation of Insulin DegludecCompletedNCT01865279Phase 1
• Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes MellitusCompletedNCT01821846
• A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy SubjectsCompletedNCT01809184Phase 1
• A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 DiabetesCompletedNCT01796366Phase 1
• A Trial to Investigate the Impact of Nocturnal Hypoglycaemia on Sleep in Subjects With Type 2 DiabetesCompletedNCT01780272Phase 1
• Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 DiabetesCompletedNCT01720303Phase 4
• Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 DiabetesCompletedNCT01720290Phase 4
• Safety of Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes MellitusCompletedNCT01709929Phase 3
• Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 DiabetesCompletedNCT01704378Phase 4
• Efficacy of Repaglinide in Subjects With Type 2 DiabetesCompletedNCT01698931Phase 4
• Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 DiabetesCompletedNCT01697631Phase 4
• Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 DiabetesCompletedNCT01697618Phase 2
• An International Survey on Hypoglycaemia Among Insulin-treated Patients With DiabetesCompletedNCT01696266
• Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male SubjectsCompletedNCT01690169Phase 1
• Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 DiabetesCompletedNCT01686945Phase 1
• Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 DiabetesCompletedNCT01650129Phase 3
• Safety and Efficacy of Insulin Aspart in Type 2 DiabetesCompletedNCT01649570Phase 4
• French Observational Survey to Assess Hypoglycaemia in Insulin-treated Diabetic PatientsCompletedNCT01628341
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese VolunteersCompletedNCT01620463Phase 1
• Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and 50 in Subjects With Type 2 DiabetesCompletedNCT01620424Phase 1
• Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 DiabetesCompletedNCT01615978Phase 1
• Effect of Repaglinide on Postprandial Lipemia in Type 2 DiabetesCompletedNCT01605773Phase 4
• A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy SubjectsCompletedNCT01597713Phase 1
• Psychosocial Factors Related to Compliance With Treatment With Biphasic Insulin AnaloguesCompletedNCT01585506